Strategic Investor Momentum Abbott led a 55 million Series B that validates strategic potential and signals strong interest from a global healthcare leader in NVision's platform. These dynamics open doors for co development, joint go to market, and platform licensing with Abbott and other pharma and medtech partners.

Clinical Imaging Advantage POLARIS hyperpolarization enables real time metabolic MRI with dramatic signal enhancement, enabling non invasive early diagnosis and treatment monitoring. Target customers include hospitals, imaging centers, diagnostic labs, and pharma R&D teams seeking advanced imaging biomarkers.

Drug Discovery Synergy PIQC Photonic Integrated Quantum Circuits offer scalable molecular qubits on photonic chips to accelerate biology modeling and drug discovery. This creates collaboration opportunities with pharma R&D, CROs, and biotech startups to speed lead discovery and validation.

Compute and Validate The compute and validate paradigm supports integration of quantum design tools into existing R&D workflows, delivering evidence of biological impact. Sales angles include joint development programs, platform partnerships, and co funded pilots with biotech and pharma organizations.

European Growth Potential Based in Ulm, NVision sits in a favorable European biotech hub with access to EU funding and healthcare networks. There is clear potential to scale sales across Europe through regional partnerships, grants, and hospital collaborations.